Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors

Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer

(2016) Vanessa F. Merino et al.   CANCER RESEARCH

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer

(2016) Ingrid A. Mayer et al.   CLINICAL CANCER RESEARCH

Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line

(2015) Ayunadirah Ayub et al.   BIOMEDICINE & PHARMACOTHERAPY

Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity

(2015) Alexandra Van Keymeulen et al.   NATURE

PIK3CAH1047R induces multipotency and multi-lineage mammary tumours

(2015) Shany Koren et al.   NATURE

An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial–mesenchymal transition and cancer stem cell expansion in human breast cancer cells

(2014) Lin Yang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

(2014) K. P. Papadopoulos et al.   CLINICAL CANCER RESEARCH

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

Mouse models ofPIK3CAmutations: one mutation initiates heterogeneous mammary tumors

(2013) Shany Koren et al.   FEBS Journal

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R

(2013) D S Meyer et al.   Oncogenesis

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

(2012) B. Markman et al.   ANNALS OF ONCOLOGY

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

(2012) Irene Brana et al.   BMC Medicine

Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

(2012) A Gallardo et al.   BRITISH JOURNAL OF CANCER

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

(2012) Adrian Britschgi et al.   CANCER CELL

Conditional activation of Pik3ca H1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations

(2012) W Yuan et al.   ONCOGENE

Physiological Levels of Pik3caH1047R Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors

(2012) Anjali Tikoo et al.   PLoS One

Molecular signatures database (MSigDB) 3.0

(2011) A. Liberzon et al.   BIOINFORMATICS

Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation

(2011) J. R. Adams et al.   CANCER RESEARCH

Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors

(2011) D. S. Meyer et al.   CANCER RESEARCH

A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer

(2011) E. M. Fox et al.   CANCER RESEARCH

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms

(2011) Pixu Liu et al.   NATURE MEDICINE

Igf2 ligand dependency of Pten+/− developmental and tumour phenotypes in the mouse

(2011) D N Church et al.   ONCOGENE

Essential role of Stat3 in PI3K-induced oncogenic transformation

(2011) Jonathan R. Hart et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

(2010) C. O'Brien et al.   CLINICAL CANCER RESEARCH

Accurate and objective copy number profiling using real-time quantitative PCR

(2010) Barbara D’haene et al.   METHODS

Gene Expression Profiling Reveals New Aspects of PIK3CA Mutation in ERalpha-Positive Breast Cancer: Major Implication of the Wnt Signaling Pathway

(2010) Magdalena Cizkova et al.   PLoS One

Identification of Novel Gene Amplifications in Breast Cancer and Coexistence of Gene Amplification with an Activating Mutation of PIK3CA

(2009) M. Kadota et al.   CANCER RESEARCH

Pygo2 expands mammary progenitor cells by facilitating histone H3 K4 methylation

(2009) Bingnan Gu et al.   JOURNAL OF CELL BIOLOGY

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

Keeping IGF-II under control: Lessons from the IGF-II–IGF2R crystal structure

(2009) James Brown et al.   TRENDS IN BIOCHEMICAL SCIENCES

Activation of Phosphatidylinositol 3-Kinase by Membrane Localization of p110  Predisposes Mammary Glands to Neoplastic Transformation

(2008) O. Renner et al.   CANCER RESEARCH

Class I PI3K in oncogenic cellular transformation

(2008) L Zhao et al.   ONCOGENE